Navigation Links
MannKind Updates Status of NDA Submission for AFRESA
Date:2/26/2009

VALENCIA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today provided an update on the status of its new drug application ("NDA") for AFRESA(R), an ultra rapid-acting insulin that has completed Phase 3 clinical trials. As previously announced, our internal goal was to submit the NDA to the Food and Drug Administration ("FDA") by the end of February. Based on editorial decisions made during the final stages of preparing the dossier, we have decided to extend the submission date by approximately three weeks.

The document is fully drafted. However, we decided during our final review that it would be preferable to remove several tens of thousands of pages of back-up data from the submission and instead make this material available to the FDA upon request. This change will significantly reduce the size of the NDA and should make the NDA more reviewer-friendly.

"Although I am mindful of our goal to submit the NDA as quickly as possible, it is more important to me that we provide the FDA with a high-quality submission that can be efficiently reviewed," said Dr. Peter Richardson, MannKind's Corporate Vice President and Chief Scientific Officer. "I am not willing to rush the final hyper-linking and quality-checking activities, especially when these efforts could potentially facilitate the FDA's review of our new drug application for AFRESA."

About AFRESA(R)

AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The pharmacokinetic profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstre
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MannKind Reports Successful Completion of Device Bioequivalence Trial
2. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
4. MannKind Addresses Pfizers Announcement Regarding Exubera
5. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
6. AAOMS Updates BRONJ Position Paper
7. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
8. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
9. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
10. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
11. Genmab Announces Updates on Phase III Cancer Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
(Date:8/19/2014)... Md. , Aug. 19, 2014  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... offering announced last Thursday, August 14, 2014, has closed.  ... are convertible at $7.30 per share of common stock.  ... months, to purchase up to an additional 30% of ...
(Date:8/19/2014)... YORK , Aug. 19, 2014  As ... around the country, Bernstein Liebhard LLP notes that ... can choose between a number of options that ... dangerous surgical instrument. According to a report published ... th , these options include a mini-laparotomy and ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... 24 Children,s Mental Focus,Foundation (CMFF), a nonprofit ... that may be linked to children with autism ... currently working with,doctors that have patients afflicted with ... adults cope with behavioral problems,associated with mental disorders ...
... Marketers, who have the,primary responsibility for communicating the ... as top challenges for pharmaceutical,companies when communicating trial ... worry about competitors stealing your,thunder, but also worry ... According to a Best Practices, LLC benchmarking study, ...
Cached Medicine Technology:Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 2Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 3Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies 2
(Date:8/20/2014)... “Have you recently been involved in an auto ... lawyer serving the greater Seattle area. “Are you still feeling ... keep reading . , In a recently released article, Dax ... accident can use to see if they may qualify for ... insurance claim will allow an individual to receive medical treatment ...
(Date:8/20/2014)... Springs, California (PRWEB) August 20, 2014 ... , designed the innovative RevitaDERM® Psoriasis Treatment ... that is associated with psoriasis. This all-in-one product ... symptoms. , RevitaDERM® Psoriasis Treatment is powered by ... odor commonly associated with this effective ingredient. ...
(Date:8/20/2014)... they often have difficulty falling asleep and staying asleep, ... In individuals with Alzheimer,s disease, this common and troubling ... leading to nighttime confusion and wandering. , Now, a ... Center (BIDMC) and the University of Toronto/Sunnybrook Health Sciences ... age. Reported online today in the journal Brain ...
(Date:8/20/2014)... GBK, the luxury lifestyle gift lounge and special events ... at the annual GBK Gift Lounge. This year’s event will ... from 11am – 6pm. GBK will offer guests an opportunity ... , As always, GBK will blend this award show celebration ... lounge. GO Campaign is a grantmaking organization that improves the ...
(Date:8/20/2014)... Kowa Optimed returns after a short ... the new SL-17 portable slit lamp. , The SL-17 ... source controlled by an illuminated thumb wheel for easy ... commercially available AAA rechargeable and dry cell batteries, which ... batteries designed specifically for the device. The new Sl-17 ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 2Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 4Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2
... source for correct information about Sex, according to a new ... in the study, conducted by the Canadian Association for Health ... disseminator about ‘Birds and The Bees’. Of course, teens also ... schools and discussion amongst friends. ,"One of ...
... flu in northwestern Germany has been steadily increasing over the ... of the 103 cases were identified outside the Baltic Sea ... been involved in collection of carcasses. ,Recently, nearly ... virus. The Institute for Animal Health in Riems had identified ...
... is on high alert to tackle any Bird Flu cases. ... of Medical Sciences (AIIMS)' and another 20// bedded ward has ... treat any of the patients with avian influenza or bird ... been the instruction to food restaurant in the city to ...
... news that that bird flu was found in chickens in a village ... change has affected Leong Hup, Farm's Best and CAB// Cakaran stockers the ... while Farm's Best shares and warrants lost 55 sen and 19.5 sen ... RM1.08. ,Among other poultry stocks, Lay Hong was ...
... Donald’s fried in another controversy which pertains to its French ... in United States over its use of wheat and milk ... contention is that these constituents might trigger allergy in some ... trans fat in a large serving of fries is higher ...
... doubts about consumption of chicken in Punjab, commonly known as ... chicken has already dropped by 30-50% over the past three ... tikka butter masala, rated as the most popular dish in ... for the past five years. Sadly, there has now been ...
Cached Medicine News:
... versatile new test providing the broadest range ... The Multi-Target Stereo test can be used ... stereopsis, visual attention, form and depth perception, ... includes a pair of high quality reversible ...
... stereo tests provide accurate measurement of ... choice of polarized glasses. The original ... slipped into a thin plastic frame ... includes Richmonds new P/N 4465 Polycarbonate ...
Comes with seven test plates. Red and green glasses filters are mounted in two frames, one for adults and one for children. Suitable for testing very small children as well as adults....
Lumicon 48 mm red filter....
Medicine Products: